Sea4Us is currently developing a novel therapy for chronic pain based on the suppression of the hyperexcitability of the pain signalling pathway, through modulation of activity of key ion channels located in neurons from the dorsal root ganglia (DRG), a “switch” to the input of pain to the brain.
Chronic pain is a syndrome, caused by various pathologies (diabetes, cancer, arthritis, fibromyalgia, shingles, etc.), that affects 1.5 billion people worldwide (21% of the world’s population). Its conditions are deep-reaching in terms of their physical, psychological, social and economic consequences, in particular since there is no adequate treatment for the most serious cases, causing a huge negative impact on society. In Portugal, for example, the weight of the direct (health care costs) and indirect costs (workplace absenteeism and low productivity) on the economy, related to chronic pain, represent nearly 3% of the gross domestic product (GDP).
The novel analgesic being developed by Sea4Us will tackle moderate to severe chronic pain types currently without adequate treatment. It has the potential to be a major breakthrough in pain management due to its novel mode of action, target specificity, effectiveness and predictable lack of noxious side effects, thus improving patients’ quality of life.